MDM2 and sarcoma: Two sarcomas (patients 10 and 21) had an MDM2 (4193) amplification (≥6-fold) that could be targeted by MDM2 inhibitors.27,28 The JAK1/2 (3716) signaling pathway was altered in 6 patients (patients 19, 20, 22, 24, 29, and 51) who could have been treated with JAK1/2 inhibitors.